Dyne Therapeutics
75 hedge funds and large institutions have $533M invested in Dyne Therapeutics in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 13 closing their positions.
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
9% more funds holding
Funds holding: 69 → 75 (+6)
2.26% more ownership
Funds ownership: 64.47% → 66.73% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less capital invested
Capital invested by funds: $614M → $533M (-$81.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$31M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$17.1M |
| 3 |
CC
Commodore Capital
New York
|
+$8.32M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$7.74M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$11.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$8.4M |
| 4 |
CCM
CAAS Capital Management
New York
|
-$3.18M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$2.1M |
DYN Hedge Fund Activity: Q1 2021 in Review
75 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2021, worth a combined $533M — down 13% from $614M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DYN positions and 13 closed out — a net gain of 6 holders — while 34 added to existing stakes and 11 trimmed.
The largest buyer was Logos Global Management, adding an estimated $31M. The largest seller was Franklin Resources, cutting an estimated $11.1M.
- 75 institutional investors held Dyne Therapeutics (DYN) as of Q1 2021, up from 69 in Q4 2020.
- Funds reported $533M of Dyne Therapeutics stock for Q1 2021, down 13% quarter-over-quarter.
- 19 funds opened new Dyne Therapeutics positions in Q1 2021 and 13 closed out, a net change of +6 holders.
- The largest Dyne Therapeutics buyer in Q1 2021 was Logos Global Management, an estimated $31M added.
- The largest Dyne Therapeutics seller in Q1 2021 was Franklin Resources, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2021.